The attenuated hepatocellular carcinoma-specific Listeria vaccine Lmdd-MPFG prevents tumor occurrence through immune regulation of dendritic cells
Metrics: PDF 1106 views | HTML 1364 views | ?
Xin Wan1, Ci Cheng1, Zhe Lin1, Runqiu Jiang2, Wei Zhao1, Xin Yan1, Junwei Tang2, Kun Yao1, Beicheng Sun2 and Yun Chen1
1 Department of Microbiology and Immunology, Nanjing Medical University, Nanjing, Jiangsu Province, China
2 Liver Transplantation Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, China
Yun Chen, email:
Beicheng Sun, email:
Keywords: Lmdd-MPFG, Hepatocellular carcinoma, dendritic cells, PRRs
Received: December 21, 2014 Accepted: February 12, 2015 Published: March 12, 2015
Immunotherapy is a promising treatment for liver cancer. Here, we tested the ability of the attenuated hepatocellular carcinoma-specific Listeria vaccine (Lmdd-MPFG) to treat hepatocellular carcinoma (HCC) in a mouse model. Immunization with the vaccine caused a strong anti-tumor response, especially in mice reinfused with dendritic cells (DCs). In mice that were also administered DCs, tumor suppression was accompanied by the strongest cytotoxic T lymphocyte response of all treatment groups and by induced differentiation of CD4+ T cells, especially Th17 cells. Additionally, the Lmdd-MPFG vaccine caused maturation of DCs in vitro. We demonstrated the synergistic effect of TLR4 and NLRP3 or NOD1 signaling pathways in LM-induced DC activation. These results suggest that the Lmdd-MPFG vaccine is a feasible strategy for preventing HCC.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.